Table III.

Univariate and multivariate analysis of risk factors for recurrence-free survival.

	Univariate analysis			Multivariate analysis
Variables	HR	95% CI	P-value	HR	95% CI	P-value
Sex (male/female)	0.922	0.591–1.440	0.722
Age (<45/≥45 years)	1.058	0.675–1.660	0.805
TNM stage (I–II/III–IV)	0.644	0.378–1.099	0.107
Tumor diameter (≤5/>5 cm)	0.699	0.438–1.118	0.135
R0 (R0/R1)	0.602	0.382–0.948	0.028
Differentiation (low)	1.000
Differentiation (moderate)	2.052	0.938–4.489	0.072
Differentiation (high)	1.355	0.491–3.742	0.557
Lymph node metastasis (positive/negative)	2.664	1.638–4.331	<0.001c	1.065	0.582–1.948	0.839
Intrahepatic metastasis (positive/negative)	5.640	3.143–10.123	<0.001c	1.517	0.722–3.187	0.271
Multiplicity (positive/negative)	4.427	2.718–7.212	<0.001c	2.898	1.564–5.369	0.001b
Vascular invasion (positive/negative)	5.100	3.017–8.619	<0.001c	2.655	1.340–5.259	0.005b
Pyruvate kinase M2 expression (high/low)	2.048	1.289–3.254	0.002b	1.567	1.057–3.012	0.006b
Diabetes mellitus (yes/no)	1.985	1.222–3.225	0.006b	1.784	1.042–3.053	0.035a
Total bilirubin (>34/≤34 µmol/l)	0.750	0.426–1.321	0.319
Alanine aminotransferase (>100/≤100 IU/l)	0.857	0.463–1.586	0.623
Prothrombin time (>14/≤14 sec)	1.134	0.414–3.104	0.807
Albumin (>35/≤35 g/l)	0.627	0.345–1.139	0.126
Aspartate aminotransferase (>100/≤100 IU/l)	1.198	0.706–2.032	0.503

^aP<0.05

^bP<0.01

^cP<0.001. HR, hazard ratio; IU, international unit.